Leon O. Moulder Jr., Chief Executive Officer of Zenas BioPharma, Inc. (NASDAQ:ZBIO), recently made significant stock purchases, according to a Form 4 filing with the Securities and Exchange Commission. Over two days, Moulder acquired a total of 70,000 shares of common stock, in transactions valued at approximately $718,100. Shares were bought at prices ranging from $9.98 to $10.76 per share, near the stock’s 52-week low of $9.45. InvestingPro data shows that the stock is currently trading at $9.84, with analyst price targets ranging from $27 to $45.
These acquisitions increase Moulder’s direct ownership of Zenas BioPharma shares to 241,155. In addition, he has an indirect interest in 1,672,039 shares through Tellus BioVentures LLC, where he is a member of the board. The move underscores Moulder’s continued investment and confidence in the company’s prospects. The company maintains a strong liquidity position with a current ratio of 8.95, and according to InvestingProit has more cash on its balance sheet than debt. Access 12 additional InvestingPro tips and comprehensive financial analysis to evaluate this insider buy.
In other recent news, Zenas Biopharma is attracting the attention of several analyst firms for its lead drug, obexelimab. Citi initiated coverage with a Buy rating, highlighting obexelimab’s potential in treating a range of diseases within the inflammatory and immune space. Morgan Stanley (NYSE: ) also expressed optimism, starting coverage with an overweight rating, citing upcoming updates on phase II and phase III trials in 2025 as key moments. Guggenheim initiated coverage with a Buy rating, highlighting obexelimab’s promising mechanism of action and potential to generate approximately $1.8 billion in risk-adjusted global peak sales. Jefferies initiated coverage with a Buy rating, estimating total peak adjusted revenues for Zenas Biopharma at approximately $1.6 billion. Zenas Biopharma is currently advancing its Phase 3 study for obexelimab in IgG4-related diseases, with results expected in late 2025. Phase 2 trials for multiple sclerosis and systemic lupus erythematosus are underway, and the data are expected in 2025 or early 2026. These recent developments indicate Zenas Biopharma’s growth potential in the near future.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
